首页> 外文期刊>Journal of mass spectrometry: JMS >Evaluation of temperature, excipients impact on the primary structure of Ganirelix in an injectable formulation, and comparison with Orgalutran (R) using MALDI-TOF/TOF-MS
【24h】

Evaluation of temperature, excipients impact on the primary structure of Ganirelix in an injectable formulation, and comparison with Orgalutran (R) using MALDI-TOF/TOF-MS

机译:温度评估,赋形剂对可注射制剂中甘雷克利克斯的主要结构的影响,并使用MALDI-TOF / TOF-MS与orgalutran(R)的比较

获取原文
获取原文并翻译 | 示例
           

摘要

Ganirelix is a linear polypeptide consisting of covalently bonded 10 amino acid residues. The amino acid sequence in a peptide determines the properties of the molecule. The slightest change in the primary structure (amino acid sequence) of therapeutic peptides can significantly impact its safety, efficacy, and immunogenicity. Hence, the primary structure analysis of therapeutic peptides is regarded as a critical quality attribute (CQA). A vast array of analytical techniques can be used to capture the primary structure of the peptide. In this study, we applied matrix-assisted laser desorption ionization (MALDI)/tandem time of flight mass spectroscopic (TOF/TOF MS) method to demonstrate the primary structure of Ganirelix in an injectable formulation. The apparent monoisotopic molecular mass of Ganirelix is 1,568.9 Da. The attained primary amino acid sequence of Ganirelix in temperature-stressed generic product matched with the theoretical sequence and showed homology with those of the reference listed drug (RLD).
机译:Ganirelix是一种由共价键合的10个氨基酸残基组成的线性多肽。肽中的氨基酸序列决定了分子的性质。治疗性肽的主要结构(氨基酸序列)的最轻微的变化可以显着影响其安全性,效力和免疫原性。因此,治疗肽的主要结构分析被认为是关键质量属性(CQA)。可以使用广泛的分析技术来捕获肽的主要结构。在该研究中,我们应用基质辅助激光解吸电离(MALDI)/串联的飞行质谱(TOF / TOF MS)方法,以证明在可注射制剂中的GANIRELIX的主要结构。 Ganirelix的表观单异点分子量为1,568.9 da。在与理论序列匹配的温度胁迫通用产物中达到甘雷氏素的主要氨基酸序列,并与参考列出的药物(RLD)的同源性显示出同源性。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号